Drug Safety Not Improved Post Vioxx

Congressional investigators are looking into why the FDA has not implemented the new guidelines for drug safety after the Vioxx debacle of 2004. After Vioxx was removed from the market drug industry safety experts called for changes in the manner in which drugs are evaluated and monitored. The guidelines called for a more active role for those who monitor the side effects of the drug. Instead, the scientists who initially approved a drug for market are still in charge of the monitoring of the drug post market.
Some Congressional leaders like Senator Charles Grassley have been openly critical of the slow progress. “No more time should be wasted at the FDA in establishing independence for its post-market surveillance,” Sen. Charles Grassley, R-Iowa, said in a statement.
In spite of clear recommendations from drug safety experts, the FDA has failed to make the change.